Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities

被引：0
|
作者：
Adu, Yaw [1 ]
Das, Saurav [2 ]
Ailawadhi, Dhaani [3 ]
Fernandez, Andre [2 ]
Parrondo, Ricardo [2 ]
Roy, Vivek [2 ]
Sher, Taimur [2 ]
O'Connell, Sean [4 ]
Rasheed, Ahsan [2 ]
Chanan-Khan, Asher A. [2 ]
Ailawadhi, Sikander [2 ]
机构：
[1] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX USA
[2] Mayo Clin, Div Hematol Oncol, Jacksonville, FL USA
[3] Bolles Middle Sch, Jacksonville, FL USA
[4] Mayo Clin, Sch Continuous Profess Dev, Jacksonville, FL USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189642
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
    Mei, Heng
    Li, Chenggong
    Jiang, Huiwen
    Zhao, Xinying
    Huang, Zhiping
    Jin, Dan
    Guo, Tao
    Kou, Haiming
    Liu, Lin
    Tang, Lu
    Yin, Ping
    Wang, Zhihui
    Ai, Lisha
    Ke, Sha
    Xia, Yimeng
    Deng, Jun
    Chen, Lei
    Cai, Li
    Sun, Chunyan
    Xia, Linghui
    Hua, Gaoquan
    Hu, Yu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [32] A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
    Heng Mei
    Chenggong Li
    Huiwen Jiang
    Xinying Zhao
    Zhiping Huang
    Dan Jin
    Tao Guo
    Haiming Kou
    Lin Liu
    Lu Tang
    Ping Yin
    Zhihui Wang
    Lisha Ai
    Sha Ke
    Yimeng Xia
    Jun Deng
    Lei Chen
    Li Cai
    Chunyan Sun
    Linghui Xia
    Gaoquan Hua
    Yu Hu
    Journal of Hematology & Oncology, 14
  • [33] High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
    Tang, Yuanyan
    Yin, Haisen
    Zhao, Xinying
    Jin, Dan
    Liang, Yan
    Xiong, Tao
    Li, Lu
    Tang, Wen
    Zhang, Jiangzhao
    Liu, Min
    Yu, Zhuojun
    Liu, Huimin
    Zang, Sibin
    Huang, Zhiping
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [34] Bispecific Antibodies Improve Outcomes in Patients With Relapsed or Refractory Multiple Myeloma After Car-T Cell Therapy
    Merz, Maximilan
    Dima, Danai
    Hashmi, Hamza
    Mueller, Fabian
    Ahmed, Nausheen
    Rathje, Kristin
    Davis, James
    Holderried, Tobias
    Vucinik, Vladan
    Kharbouti, Soraya
    Ayuk, Francis
    Stoelzel, Friedrich
    Schub, Natalie
    Schmitz, Friederike
    Shune, Leyla
    Khouri, Jack
    Anwer, Faiz
    McGuirk, Joseph
    Teichert, Marcel
    von Tresckow, Bastian
    Kroeger, Nicolaus
    Pabst, Thomas
    Abdallah, Al-Ola
    Gagelmann, Nico
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S73 - S74
  • [35] Real-World Disparities in Daratumumab Utilization for Patients with Relapsed or Refractory Multiple Myeloma (MM)
    Maignan, Kathleen
    Backenroth, Daniel
    McQuarrie, Neil A.
    Lipitz, Nicole G.
    Williams, Erin R.
    Carson, Kenneth R.
    BLOOD, 2018, 132
  • [36] Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
    Sidana, Surbhi
    Ahmed, Nausheen
    Akhtar, Othman S.
    Heim, Michael
    Brazauskas, Ruta
    Hansen, Doris K.
    Ferreri, Christopher
    Freeman, Ciara Louise L.
    Afrough, Aimaz
    Anderson, Larry D., Jr.
    Dhakal, Binod
    Dhanda, Devender
    Gowda, Lohith
    Hashmi, Hamza
    Harrison, Melanie
    Kitali, Amani
    Mirza, Sayeef
    Patel, Jinalben
    Patwardhan, Pallavi
    Usmani, Saad Z.
    Patel, Krina K.
    Ganguly, Siddhartha
    Pasquini, Marcelo
    BLOOD, 2023, 142
  • [37] BCMA x CD3 bispecific antibody treatment with teclistamab in relapsed and/or refractory multiple myeloma: a real-world monocentric analysis
    Schaefers, C.
    Thiele, B.
    Alsdorf, W.
    Kosch, R.
    Leypoldt, L.
    Bokemeyer, C.
    Weisel, K.
    Kamili, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 312 - 312
  • [38] CAR-T Therapy Versus Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: Systematic Review and Metanalysis of Toxicity and Response
    Mehta, Mansi
    Namjoshi, Devang
    Fernandes, Bolivia Crocete Aloysia
    Mukhtiar, Vaibhavi
    Bhanushali, Charmi
    Kumar, Madhan Srinivasan
    Rana, Gunjan
    Santhi, Jaison Lawrence Alexander
    Mishra, Tanisha
    Ramanathan, Muthalagu
    BLOOD, 2024, 144 : 6929 - 6930
  • [39] Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
    Zah, Eugenia
    Nam, Eunwoo
    Bhuvan, Vinya
    Tran, Uyen
    Ji, Brenda Y.
    Gosliner, Stanley B.
    Wang, Xiuli
    Brown, Christine E.
    Chen, Yvonne Y.
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [40] Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
    Eugenia Zah
    Eunwoo Nam
    Vinya Bhuvan
    Uyen Tran
    Brenda Y. Ji
    Stanley B. Gosliner
    Xiuli Wang
    Christine E. Brown
    Yvonne Y. Chen
    Nature Communications, 11
12345